Addendum
Upadacitinib (giant cell arteritis) – Addendum to Project A25-66
Report documents
-
Addendum
Upadacitinib (giant cell arteritis) – Addendum to Project A25-66
Dossier assessment
Indication:
Adults with giant cell arteritis
Result of dossier assessment:
- Patients who are candidates for therapy with glucocorticoids alone: unchanged after addendum: added benefit not proven
- Patients who are not candidates for therapy with glucocorticoids alone: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-11-06 A G-BA decision was published.
Project details
- Project no.
- A25-125
- Commission
- Commission awarded on 23.09.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-125_en
Connected Projects
-
Dossier assessment
Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed